BDR Pharma Says BMS Misleads Delhi High Court Over Sprycel CL
This article was originally published in PharmAsia News
Executive Summary
An India drug maker seeking a compulsory license to market a generic of a Bristol-Myers Squibb's Sprycel (dasatinib) cancer drug accused the U.S. firm of lying to the Delhi High Court over the status of BDR Pharma's application.